Abstract
Neuropathy pain is one chronic pain that is difficult to treat and has not had an ideal curative therapy, yet. Gabapentin and amitriptyline are widely used as diabetic neuropathy therapies. However, their effectiveness is still debatable and their side effect has been reported. Several factors affect the efficacy and morbidity of gabapentin and amitriptyline in diabetic neuropathy patients. Some treatment options for diabetic neuropathy are available in clinical setting, therefore evaluation the effectiveness of the treatment options is needed to choose the best treatment. This review article evaluated the effectiveness and safety between gabapentin and amitriptyline as pain relief in peripheral diabetic neuropathy (PDN) patients. It was a narrative review using electronic databases such as Science Direct, Scopus and PubMed. The results showed that effectiveness and safety of gabapentin is better than amitriptyline in relief pain on PDN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
